Literature DB >> 12825828

1,4-Dihydropyridines as calcium channel ligands and privileged structures.

David J Triggle1.   

Abstract

1. The 1,4-dihydropyridine nucleus serves as the scaffold for important cardiovascular drugs-calcium antagonists-including nifedipine, nitrendipine, amlodipine, and nisoldipine, which exert their antihypertensive and antianginal actions through actions at voltage-gated calcium channels of the CaV1 (L-type) class. 2. These drugs act at a specific receptor site for which defined structure-activity relationships exist, including stereoselectivity. 3. Despite the widespread occurrence of the CaV1 class of channel, the calcium antagonists exhibit significant selectivity of action in the cardiovascular system. This selectivity arises from a number of factors including subtype of channel, state-dependent interactions. pharmacokinetics, and mode of calcium mobilization. 4. The 1,4-dihydropyridine nucleus is also a privileged structure or scaffold that can, when appropriately decorated substituents, interact at diverse receptors and ion channels, including potassium and sodium channels and receptors of the G-protein class.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12825828     DOI: 10.1023/a:1023632419813

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  45 in total

1.  Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.

Authors:  J Jiang; A H Li; S Y Jang; L Chang; N Melman; S Moro; X Ji; E B Lobkovsky; J C Clardy; K A Jacobson
Journal:  J Med Chem       Date:  1999-08-12       Impact factor: 7.446

Review 2.  Target-oriented and diversity-oriented organic synthesis in drug discovery.

Authors:  S L Schreiber
Journal:  Science       Date:  2000-03-17       Impact factor: 47.728

3.  Conopeptides: From deadly venoms to novel therapeutics.

Authors: 
Journal:  Drug Discov Today       Date:  2000-03       Impact factor: 7.851

4.  Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.

Authors:  H Hu; E Marban
Journal:  Mol Pharmacol       Date:  1998-05       Impact factor: 4.436

Review 5.  Calcium antagonists. History and perspective.

Authors:  D J Triggle
Journal:  Stroke       Date:  1990-12       Impact factor: 7.914

Review 6.  Structural basis of drug binding to L Ca2+ channels.

Authors:  J Striessnig; M Grabner; J Mitterdorfer; S Hering; M J Sinnegger; H Glossmann
Journal:  Trends Pharmacol Sci       Date:  1998-03       Impact factor: 14.819

7.  Interactions of dihydropyridine Ca2+ channel agonists with the human platelet thromboxane A2/prostaglandin H2 receptor.

Authors:  P R Mayeux; D E Mais; P V Halushka
Journal:  Eur J Pharmacol       Date:  1991-01-25       Impact factor: 4.432

Review 8.  Speciation of cone snails and interspecific hyperdivergence of their venom peptides. Potential evolutionary significance of introns.

Authors:  B M Olivera; C Walker; G E Cartier; D Hooper; A D Santos; R Schoenfeld; R Shetty; M Watkins; P Bandyopadhyay; D R Hillyard
Journal:  Ann N Y Acad Sci       Date:  1999-05-18       Impact factor: 5.691

9.  The dihydropyridine nitrendipine reduces N-methyl-D-aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel.

Authors:  G A Skeen; H S White; R E Twyman
Journal:  J Pharmacol Exp Ther       Date:  1994-10       Impact factor: 4.030

10.  The dihydropyridine nitrendipine modulates N-methyl-D-aspartate receptor channel function in mammalian neurons.

Authors:  G A Skeen; R E Twyman; H S White
Journal:  Mol Pharmacol       Date:  1993-08       Impact factor: 4.436

View more
  39 in total

1.  Alternative splicing modulates diltiazem sensitivity of cardiac and vascular smooth muscle Ca(v)1.2 calcium channels.

Authors:  Heng Yu Zhang; Ping Liao; Jue Jin Wang; De Jie Yu; Tuck Wah Soong
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  An efficient, multicomponent approach for solvent-free synthesis of 2-amino-4H-chromene scaffold.

Authors:  M Reza Naimi-Jamal; Sara Mashkouri; Ali Sharifi
Journal:  Mol Divers       Date:  2010-04-07       Impact factor: 2.943

3.  Dynamic monitoring of beating periodicity of stem cell-derived cardiomyocytes as a predictive tool for preclinical safety assessment.

Authors:  Yama A Abassi; Biao Xi; Nan Li; Wei Ouyang; Alexander Seiler; Manfred Watzele; Ralf Kettenhofen; Heribert Bohlen; Andreas Ehlich; Eugen Kolossov; Xiaobo Wang; Xiao Xu
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  Vascular effects of calcium channel antagonists: new evidence.

Authors:  Sylvain Richard
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Disrupting calcium channel expression to lower blood pressure: new targeting of a well-known channel.

Authors:  Swapnil Sonkusare; Mony Fraer; James D Marsh; Nancy J Rusch
Journal:  Mol Interv       Date:  2006-12

6.  Vascular smooth muscle-specific knockdown of the noncardiac form of the L-type calcium channel by microRNA-based short hairpin RNA as a potential antihypertensive therapy.

Authors:  Sung W Rhee; Joseph R Stimers; Wenze Wang; Li Pang
Journal:  J Pharmacol Exp Ther       Date:  2009-02-24       Impact factor: 4.030

7.  Molecular pharmacology of human Cav3.2 T-type Ca2+ channels: block by antihypertensives, antiarrhythmics, and their analogs.

Authors:  Edward Perez-Reyes; Amy L Van Deusen; Iuliia Vitko
Journal:  J Pharmacol Exp Ther       Date:  2008-10-30       Impact factor: 4.030

Review 8.  Peripheral chemoreceptors: function and plasticity of the carotid body.

Authors:  Prem Kumar; Nanduri R Prabhakar
Journal:  Compr Physiol       Date:  2012-01       Impact factor: 9.090

9.  The effect of bromine scanning around the phenyl group of 4-phenylquinolone derivatives.

Authors:  Scott A Steiger; Anthony J Monacelli; Chun Li; Janet L Hunting; Nicholas R Natale
Journal:  Acta Crystallogr C Struct Chem       Date:  2014-07-31       Impact factor: 1.172

10.  CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease.

Authors:  Soosung Kang; Garry Cooper; Sara F Dunne; Brendon Dusel; Chi-Hao Luan; D James Surmeier; Richard B Silverman
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.